Parion Sciences, Inc.

Kala Pharmaceuticals Inc. is planning to file a new drug application in the US for what it hopes will become the first FDA-approved treatment for short-term dry eye disease, specifically dry eye flar

While Allergan PLC and Shire PLC are jockeying for supremacy in the dry eye disease space, with the former's Restasis (cyclosporine ophthalmic emulsion) losing market share to the latter's

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer

Shire 's bid to further boost its presence in the dry eye disease market has been boosted by the submission of lifitegrast in Europe. The company says that the marketing authorization application for